Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.60 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31727854 | 0.79 | CES1 (0.60) | CES1DAONSD2BCHELIG1 | |
| SCHEMBL3085898 | 0.77 | CES1 (0.62) | CES1DAONSD2BCHELIG1 | |
| SCHEMBL29689346 | 0.77 | CES1 (0.62) | CES1DAONSD2BCHELIG1 | |
| Toluene SCHEMBL28094090 | 0.76 | CES1 (0.79) | CES1DAONSD2BCHELIG1 | |
| Ethane SCHEMBL28094093 | 0.76 | CES1 (0.93) | CES1DAONSD2BCHELIG1 | |
| SCHEMBL2892415 | 0.76 | CES1 (0.67) | CES1DAONSD2BCHELIG1 | |
| SCHEMBL594546 | 0.75 | CES1 (1.00) | CES1DAONSD2BCHELIG1 | |
| Methane SCHEMBL28257010 | 0.74 | CES1 (0.96) | CES1DAONSD2BCHELIG1 | |
| SCHEMBL1091746 | 0.74 | CES1 (0.59) | CES1DAONSD2BCHELIG1 | |
| SCHEMBL1092103 | 0.73 | CES1 (0.62) | CES1DAONSD2BCHELIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479175-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly and Company (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2008129075-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS | TOPOTARGET A/S (DK) | 2008-10-30 | — | — | WO | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | CES1 20/4885DAO 2557/4885NSD2 4008/4885 |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TPH2, TPH1, HTR2C | CES1 3688/4885DAO 1360/4885NSD2 2543/4885 |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | APOB, CETP, PCSK9 | CES1 26/4885DAO 3694/4885NSD2 2836/4885 |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, LIPC, PCSK9 | CES1 26/4885DAO 3699/4885NSD2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.